Microbot Medical Inc. (Nasdaq: MBOT) announced on October 6, 2026, that it has entered into a three-year exclusive commercial distribution agreement with Medtechnica Ltd. to market and sell the Company’s LIBERTY Endovascular Robotic System throughout Israel.
Medtechnica Ltd. is a leading medical device distributor in Israel. The agreement grants Medtechnica exclusive rights to distribute the LIBERTY System within the country. The Company noted that it received regulatory approval from the Israeli Ministry of Health’s AMAR Division and was registered in the Israeli Medical Device Registry (AMAR) in May 2026.
Microbot Medical anticipates that initial orders from Medtechnica Ltd. under this agreement will occur during the fourth quarter of 2026. The Company stated that this partnership is part of its international markets strategy to engage with distributors in developed markets in preparation for potential future market entry outside of the United States.
In a statement regarding the agreement, Harel Gadot, CEO, President, and Chairman of Microbot Medical, commented, “We are excited to partner with Medtechnica Ltd., whose market expertise in the endovascular space and reputation make them an ideal partner to bring LIBERTY to physicians and patients throughout Israel.”
The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain for medical professionals.
